Holen Sie sich die Stockscreener-App
121.76
1.43%
-1.77
Handel nachbörslich:
121.85
0.09
+0.07%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$123.53
Offen:
$123.23
24-Stunden-Volumen:
10.33M
Relative Volume:
1.65
Marktkapitalisierung:
$211.73B
Einnahmen:
$43.84B
Nettoeinkommen (Verlust:
$13.90B
KGV:
15.27
EPS:
7.9725
Netto-Cashflow:
$6.92B
1W Leistung:
-3.30%
1M Leistung:
-4.02%
6M Leistung:
-7.58%
1J Leistung:
+6.89%
1-Tages-Spanne:
$121.53
$123.49
1-Wochen-Bereich:
$121.53
$126.61
52-Wochen-Spanne:
$113.39
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
121.76 | 214.80B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
363.78 | 138.62B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
88.07 | 133.46B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
96.76 | 126.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.35 | 49.03B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Abbott stock drops, ABT traders eye earnings after MLK Day shuts Wall Street - TechStock²
Abbott Laboratories: Who is the newcomer to Pōkeno? - BusinessDesk | NZ
Abbott Laboratories (ABT) positioned to benefit as healthcare sector enters recovery phase - MSN
Abbott Laboratories (ABT) Positioned to Benefit as Healthcare Sector Enters Recovery Phase - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Stands Out as a Dependable Dividend Stock for Income Investors - Chartmill
Is Abbott Laboratories (ABT) Price Weakness Creating A Potential Opportunity Now? - Yahoo Finance
Abbott (ABT) Declines More Than Market: Some Information for Investors - Yahoo Finance Singapore
Options Corner: Abbott Laboratories Offer Economic Insulation Ahead Of Earnings - Benzinga
FDA confirms recalls for Abbott CGM sensors—new lawsuit alleges company concealed information - Cardiovascular Business
TorHoerman Law Announces $495 Million Jury Verdict in Case Involving Abbott Laboratories - ACCESS Newswire
1 Healthcare Stock to Consider Right Now and 2 We Find Risky - FinancialContent
Assessing Abbott Laboratories (ABT) Valuation After The CES 2026 Launch Of Libre Assist AI Tool - simplywall.st
Dividend King Abbott Shows Why 52 Consecutive Increases Weren’t Luck With Strong Cash Flow Coverage - AOL.com
Abbott reportedly looks to expand CGM manufacturing plant in Ireland - MassDevice
C-Reactive Protein Testing Market Is Going to Boom |• Abbott • Siemens Healthineers - openPR.com
Nordea Investment Management AB Buys 18,974 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Shares Unloaded Rep. Julia Letlow - MarketBeat
Abbott Laboratories (ABT) Expected to Announce Earnings on Thursday - MarketBeat
Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories Target of Unusually Large Options Trading (NYSE:ABT) - MarketBeat
Retirement Planning Group LLC Grows Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stock Holdings Cut by Exencial Wealth Advisors LLC - MarketBeat
The Bull Case For Abbott Laboratories (ABT) Could Change Following Libre Assist AI Launch In Diabetes Care - simplywall.st
Gov't Didn't Allege Formula Was Contaminated, Abbott Says - Law360
ABT.SW Abbott Laboratories (SIX) volume spike 13 Jan 2026: CHF100 key - Meyka
Bernstein Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $154 - 富途牛牛
Why Abbott Laboratories (ABT) Story Is Shifting With Exact Sciences Deal Talk And Legal Wins - Yahoo Finance
Abbott, AtaCor Collaborate on Extravascular Implantable Cardioverter Defibrillator - Diagnostic and Interventional Cardiology
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Declares Quarterly Dividend of $0.63 - MarketBeat
MGO One Seven LLC Acquires 18,412 Shares of Abbott Laboratories $ABT - MarketBeat
Extracorporeal Membrane Oxygenation Machine Market Size to Hit USD 725.99 Million by 2033, Growing at a CAGR of 4.91% - GlobeNewswire Inc.
Abbott Laboratories (NYSE:ABT) is favoured by institutional owners who hold 80% of the company - Yahoo Finance
GRIMES & Co WEALTH MANAGEMENT LLC Purchases 10,635 Shares of Abbott Laboratories $ABT - MarketBeat
CPC Advisors LLC Grows Stock Holdings in Abbott Laboratories $ABT - MarketBeat
AbbVie reaches deal with Trump administration on drug prices in exchange for tariff relief - Chicago Tribune
Abbott Laboratories Stock: Quiet Grind Higher as Wall Street Warms to the Recovery Story - AD HOC NEWS
Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Institutional Investors Show Confidence in Abbott’s Healthcare Strategy - AD HOC NEWS
Is the Market Bullish or Bearish on Abbott Laboratories? - Benzinga
Abbott (ABT) Gains Ground in Glucose Monitoring Market - GuruFocus
Abbott, AtaCor collab on extravascular ICDs - MassDevice
Abbott Laboratories (ABT) Investor Outlook: Exploring a 14.95% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Abbott Laboratories $ABT Shares Acquired by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Biomedical and ICT Convergence Market Research Report 2025-2030: Opportunities in Developing Connected Medical Devices, Enhancing Precision Medicine, and Improving Healthcare Delivery - GlobeNewswire Inc.
Tema Etfs LLC Raises Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA - MarketBeat
Abbott Laboratories stock (ABT) in focus: Exact Sciences vote date lands as earnings week nears - TechStock²
Abbott Laboratories $ABT Shares Sold by New York State Teachers Retirement System - MarketBeat
Abbott Laboratories stock drifts into earnings after Canada widens Libre 3 Plus coverage - TechStock²
Parnassus Investments LLC Acquires New Shares in Abbott Laboratories $ABT - MarketBeat
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
2.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):